Ge Long Hui·2026-02-27 11:20Core Insights - Rongchang Biopharma (09995.HK) reported a significant increase in revenue and net profit for the fiscal year 2025, with total revenue reaching RMB 3.25 billion, a year-on-year increase of 89.36% [1] - The company achieved a net profit attributable to shareholders of RMB 700 million, and a net profit of RMB 650.56 million after deducting non-recurring gains and losses [1] - Total assets at the end of the reporting period amounted to RMB 7.24 billion, reflecting a growth of 31.65% compared to the beginning of the period [1] Financial Performance - The equity attributable to shareholders increased by 81.40% to RMB 3.60 billion [1] - Core products, including Taitasip and Vidisicimab, saw rapid growth in domestic sales, becoming the main drivers of the company's performance [1] - The company successfully established a significant partnership with VorBiopharma Inc., granting exclusive global development and commercialization rights for Taitasip outside Greater China, leading to a substantial increase in technology licensing revenue [1] Operational Efficiency - The company implemented management optimizations and production process iterations, resulting in reduced unit production costs and improved gross profit margins [1] - A notable decrease in sales expense ratio contributed to the overall improvement in profitability efficiency [1] - The company anticipates a turnaround in net profit for the fiscal year 2025, projecting a return to profitability [1]